Growing sales of Live Vaccines Market to Reach USD 24.95 billion by 2026 at 6.6%. CAGR | Top Players Merck & Co., GlaxoSmithKline plc., Pfizer Inc., Astellas Pharma Inc., Emergent BioSolutions, AstraZeneca plc.

The Global Live Vaccines Market was valued at USD 15.15 billion in 2018 and is expected to reach USD 24.95 billion by the year 2026, at a CAGR of 6.6%. Live vaccines are derived from disease causing viruses or bacterial strains, these diseases causing bodies are attenuated or weekend by repeated culturing, which is then replicates into the individual body once is injected in response body develops immune and targets the infectious disease.

Request for FREE sample report @ https://www.reportsanddata.com/sample-enquiry-form/2078

The live vaccines market is driven due to the increasing prevalence of infectious disease such as typhoid, across the globe. As per an estimation, around 11-21 million new cases of typhoid are registered worldwide. Approximately 10.0 million cases across the globe, were diagnosed with tuberculosis in 2017. Rising awareness among the public as well as favorable government initiatives is supporting the market growth in developing nations. For example, Indian government started Pulse Polio in India, which aims to approach 100% population irrespective of literacy, financial capability, and to all geographical regions of India by aiming majorly social media.

In market segmentation by manufacturers, the report covers the following companies- include Merck & Co., GlaxoSmithKline plc., Pfizer Inc., Astellas Pharma Inc., Emergent BioSolutions, AstraZeneca plc, Serum Institute of India Pvt. Ltd., Bharat Biotech, Sun Pharmaceutical Industries Limited, and Cipla Limited

Global Polio Eradication Initiative (GEPI) funds are managed by various public and private sector donors. Furthermore, according to the recent news, England is no more measles free state due to approximately 931 new cases were registered in England and Wales in 2018 and around 231 new cases in England were diagnosed with measles in the first quarter of 2019. The global burden of such diseases is contributing towards the growth of live vaccines market.

Scope Of The Report:

The Live Vaccines Market report analyzes the present competitive landscape, underlining the ventures undertaken by the key players in the industry. Strategic initiatives such as product launches, collaborations, joint ventures, mergers and acquisitions, partnerships, and other such activities have been assessed in this report, predicting the potential revenue generation associated with such deals and launches. Furthermore, the report divides the Live Vaccines Market based on segments like products, end-users, applications, business verticals, and regional markets.

The study also gives a comprehensive outlook of drivers, constraints, growth prospects, and hurdles impacting the overall market along with market estimation derived by both top-down and bottom-up approaches and forecasts of the expected growth in the market value and volume.

For the purpose of this report, Reports and Data has segmented the live vaccines market on the basis of type, route of administration, application, patient use and region:

Type Outlook (Revenue, USD Million; 2019-2026)
Viral
Bacterial

Route of Administration Outlook (Revenue, USD Million; 2019-2026)
Oral
Injection
Intra-Nasal

Combination of Injection and Oral
Patch
Inhalation

Get Your Copy at Discounted Price @ https://www.reportsanddata.com/discount-enquiry-form/2078

Application Outlook (Revenue, USD Million; 2019-2026)
Measles
Mumps
Rubella
Varicella
Yellow Fever
Rotavirus
BCG
Others

Patient Use Outlook (Revenue, USD Million; 2019-2026)
Adults
Children

Regional Outlook (Revenue in USD Million; 2019-2026)
North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Global Competitive Landscape:

The key participants that control a considerable portion of the Live Vaccines Marketare actively employing the resources at their disposal to bring about long-standing development changes. The global industry is undergoing considerable transformation, accelerating the growth of the overall market. The available growth opportunities for the sector can be capitalized on through on-going process improvements and keeping up with the economic volatility to dedicate resources to promising expansion plans.

Live vaccines are preferable over other types of vaccination as it requires short dose, and in general, a single dose of live vaccines can provide lifetime immunity against the respective disease. Introduction of advanced technology such as live recombinant vaccine also supports the market growth. Live recombinant vaccine uses virus or bacterial strains that involves a specific gene from victim's DNA which is responsible in production of protein to target the pathogen causing disease, and produces immunity vaccines. Live recombinant vaccine are generally used for infectious diseases such as smallpox, influenza, hepatitis B and rabies.

User friendly technologies to support easy vaccine delivery has been launched in past few years; such as inhaled vaccine, delivery of influenza vaccine as a nasal spray, and delivery of vaccines through patch (that involves tiny needles). Such routes of vaccine delivery are advantageous for the use in remote area with dearth of clinicians. Such technological advancements are expected to boost the market growth.

Further key findings from the report suggest
During 2019-2026, live vaccines market is expected to register a CAGR of 2% in Asia Pacific; followed by North America and Europe, with 6.4% and 6.5% CAGR, respectively. High prevalence of infectious diseases across the globe is the major factor driving the market during the forecast period across all regions.

Based on type, the viral type of live vaccines segment dominates the market holding over 60% market share.

Asia Pacific accounted for the USD 3.44 billion of the global live vaccines market. Developing nations such China, and India are likely to witness high growth due to high population growth, high geriatric population in the region, and high prevalence of target diseases in the region

Key players operating in live vaccines market are enhancing their market business through inorganic strategies such as geographic expansion. For instance, in 2019, Sanofi Pasteur started its new state-of-the-art YF-VAX (Yellow Fever Vaccine) production plantation in U.S.

Slow rate of commercialization, high costs involved in research and development, reluctance toward the adoption of new treatment practices and stringent government regulations are among the key factors likely to hamper growth of the market

The measles segment dominates the market with a 24.8% market share in the year 2018. It is estimated to grow at a CAGR of 7.1% during the forecast period to reach USD 6.41 billion by 2026, as more number of patients are suffering from measles

The injection route for the administration of live vaccines segment is forecasted to be the fastest growing market segment, estimated to witness a CAGR of 6.8%. Parenteral route or injection for the administration is required for vaccines that cannot be administered orally, due to the factors such as destruction of vaccine by digestive enzymes.

Access Full Report Description, TOC, Figure, Chart, etc. @https://www.reportsanddata.com/report-detail/live-vaccines-market

Reasons for Purchasing the Global Live Vaccines Market Report:

The report gives a detailed description of different market elements and the changing competitive landscape, helping the reader gain a competitive edge.

It also takes a holistic approach to give a 360 view of the industry, listing the drivers and restraints existing in the market.

The Global Live Vaccines Market intelligence report offers accurate market insights for a period of eight years, which have been derived after an in-depth evaluation of industry-wide data.

The data provided in the report is intended to help readers make business decisions to capitalize on the existing opportunities in the key market segments and sub-segments.

The growth of this Live Vaccines Market across the globe is dependent on multiple factors; including consumer base of several Keyword products, inorganic growth models adopted by companies, price volatility of feed stocks, and product innovation, along with their economic prospects in both producer and consumer nations.

Contact Us:

John Watson
Head of Business Development
Direct Line: 212-710-1370
E-mail: sales@reportsanddata.com
40 Wall St. 28th floor New York City, NY 10005 United States

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.